by Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U. Clinical Infectious Diseases, December 2007, 45:1435-1442.
Summary: Current treatment options for patients with second-stage disease are either highly toxic or impracticable in field conditions. The article compares the efficacy and safety of the nifurtimox-eflornithine drug combination with the standard eflornithine regimen for the treatment of second-stage disease. The nifurtimox-eflornithine combination appears to be a promising first-line therapy for second-stage sleeping sickness.
